Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Papillomavirus Infections 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Leukemia, Lymphocytic, Chronic, B-Cell 1COVID-19 1

Interventions

human papillomavirus vaccine, L1 type 16, 18 22Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 15Papillomavirus Vaccines 9Vaccines 6Blood Specimen Collection 4Watchful Waiting 2Vaccines, Synthetic 2Light Coagulation 2Hepatitis A Vaccines 2Engerix-B 2lime 1halofantrine 1Sodium Chloride 1Radiotherapy, Intensity-Modulated 1Pentetic Acid 1Olive Oil 1Observation 1Measles-Mumps-Rubella Vaccine 1Laser Therapy 1Injections 1Imiquimod 1Human Papillomavirus DNA Tests 1Fluorouracil 1Diphtheria-Tetanus-acellular Pertussis Vaccines 1DTPa-HBV-IPV combined vaccine 1Colposcopy 1Clinical Protocols 1Cisplatin 1Circumcision, Male 1Chorionic Villi Sampling 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Papillomavirus Infections × 2019-nCoV Vaccine mRNA-1273 × Clear all
NCT05119855 2026-02-05

Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076)

Merck Sharp & Dohme LLC

Phase 3 Completed
165 enrolled 13 charts

COVID-19, Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡